1H-Benzimidazole, 2,2'-[1-[(2-methoxyphenyl)methyl]-1,2-ethanediyl]bis- (9CI)

DBMB is an inhibitor of spleen tyrosine kinase (Syk), capable of significantly inhibiting the activity of Syk kinase. DBMB exhibits anti-inflammatory activity by suppressing the signaling of NF-κB, which in turn reduces the production of inflammatory mediators such as nitric oxide (NO) and prostaglandin E2 (PGE2). DBMB can be utilized in research on inflammatory diseases[1].

[1] Kim E, et al. 1-(2, 3-dibenzimidazol-2-ylpropyl)-2-methoxybenzene is a Syk inhibitor with anti-inflammatory properties[J]. Molecules, 2016, 21(4): 508. DOI:10.3390/molecules21040508